THEDACARE MED CTR - WILD ROSE — History
CCN 521303 | 3-year financial timeline | COVID resilience: 51/100
🛡️ Public data only — no PHI permitted on this instance.
$13M
Latest Revenue (FY2022)
+5.7%
Revenue CAGR (3yr)
-2.6%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $12M | $13M | $13M | -3.3% | +5.7% |
| Operating Expenses | $11M | $13M | $13M | +2.7% | +7.6% |
| Operating Margin | 1.1% | 3.4% | -2.6% | -175.3% | +0.0% |
| Net Income | $0M | $0M | $-0M | -172.7% | +0.0% |
| Licensed Beds | 25 | 25 | 25 | +0.0% | +0.0% |
| Total Patient Days | 1,598 | 1,688 | 1,483 | -12.1% | -3.7% |
| Medicare Day % | 32% | 28% | 43% | +53.0% | +16.2% |
| Medicaid Day % | 0% | 0% | 0% | -35.0% | -7.2% |
COVID Impact & Recovery
Resilience Score: 51/100 — Stressed — slow recovery from COVID
Revenue recovery from FY2020 to FY2022: +11.6% ($12M → $13M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▼ Declining
Beds▶ Stable
Medicare Mix▼ Declining
vs State Average ()
Revenue Growth
+5.7%
This Hospital
+7.6%
State Avg
Latest Margin
-2.6%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $14M | -4.4% |
| FY2024 (proj) | $14M | -6.3% |
| FY2025 (proj) | $15M | -8.1% |